Last reviewed · How we verify

Tamoxifen and GnRH analogue

GBG Forschungs GmbH · Phase 3 active Small molecule

Tamoxifen and GnRH analogue is a Selective estrogen receptor modulator (SERM) and Gonadotropin-releasing hormone (GnRH) analogue Small molecule drug developed by GBG Forschungs GmbH. It is currently in Phase 3 development for Treatment of hormone receptor-positive metastatic breast cancer, Treatment of hormone-sensitive breast cancer. Also known as: TRENATONE, ZOLADEX.

Tamoxifen acts as a selective estrogen receptor modulator (SERM) to inhibit estrogen's proliferative effects on breast cancer cells, while GnRH analogue works by downregulating GnRH receptors in the pituitary gland, leading to decreased gonadotropin secretion and subsequently reduced estrogen production.

Tamoxifen acts as a selective estrogen receptor modulator (SERM) to inhibit estrogen's proliferative effects on breast cancer cells, while GnRH analogue works by downregulating GnRH receptors in the pituitary gland, leading to decreased gonadotropin secretion and subsequently reduced estrogen production. Used for Treatment of hormone receptor-positive metastatic breast cancer, Treatment of hormone-sensitive breast cancer.

At a glance

Generic nameTamoxifen and GnRH analogue
Also known asTRENATONE, ZOLADEX
SponsorGBG Forschungs GmbH
Drug classSelective estrogen receptor modulator (SERM) and Gonadotropin-releasing hormone (GnRH) analogue
TargetEstrogen receptor and GnRH receptor
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Tamoxifen binds to estrogen receptors on breast cancer cells, preventing estrogen from binding and stimulating cell growth. This results in the inhibition of estrogen's proliferative effects on breast cancer cells. GnRH analogue, on the other hand, works by binding to GnRH receptors in the pituitary gland, leading to a decrease in gonadotropin secretion. This decrease in gonadotropin secretion subsequently results in reduced estrogen production, which can help to slow the growth of hormone receptor-positive breast cancer cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Tamoxifen and GnRH analogue

What is Tamoxifen and GnRH analogue?

Tamoxifen and GnRH analogue is a Selective estrogen receptor modulator (SERM) and Gonadotropin-releasing hormone (GnRH) analogue drug developed by GBG Forschungs GmbH, indicated for Treatment of hormone receptor-positive metastatic breast cancer, Treatment of hormone-sensitive breast cancer.

How does Tamoxifen and GnRH analogue work?

Tamoxifen acts as a selective estrogen receptor modulator (SERM) to inhibit estrogen's proliferative effects on breast cancer cells, while GnRH analogue works by downregulating GnRH receptors in the pituitary gland, leading to decreased gonadotropin secretion and subsequently reduced estrogen production.

What is Tamoxifen and GnRH analogue used for?

Tamoxifen and GnRH analogue is indicated for Treatment of hormone receptor-positive metastatic breast cancer, Treatment of hormone-sensitive breast cancer.

Who makes Tamoxifen and GnRH analogue?

Tamoxifen and GnRH analogue is developed by GBG Forschungs GmbH (see full GBG Forschungs GmbH pipeline at /company/gbg-forschungs-gmbh).

Is Tamoxifen and GnRH analogue also known as anything else?

Tamoxifen and GnRH analogue is also known as TRENATONE, ZOLADEX.

What drug class is Tamoxifen and GnRH analogue in?

Tamoxifen and GnRH analogue belongs to the Selective estrogen receptor modulator (SERM) and Gonadotropin-releasing hormone (GnRH) analogue class. See all Selective estrogen receptor modulator (SERM) and Gonadotropin-releasing hormone (GnRH) analogue drugs at /class/selective-estrogen-receptor-modulator-serm-and-gonadotropin-releasing-hormone-gnrh-analogue.

What development phase is Tamoxifen and GnRH analogue in?

Tamoxifen and GnRH analogue is in Phase 3.

What are the side effects of Tamoxifen and GnRH analogue?

Common side effects of Tamoxifen and GnRH analogue include Hot flashes, Vaginal discharge, Nausea, Headache, Fatigue.

What does Tamoxifen and GnRH analogue target?

Tamoxifen and GnRH analogue targets Estrogen receptor and GnRH receptor and is a Selective estrogen receptor modulator (SERM) and Gonadotropin-releasing hormone (GnRH) analogue.

Related